These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

167 related articles for article (PubMed ID: 8596376)

  • 1. Prevention of deep-vein thrombosis after total hip replacement: direct thrombin inhibition with recombinant hirudin, CGP 39393.
    Eriksson BI; Ekman S; Kalebo P; Zachrisson B; Bach D; Close P
    Lancet; 1996 Mar; 347(9002):635-9. PubMed ID: 8596376
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Prevention of thromboembolism with use of recombinant hirudin. Results of a double-blind, multicenter trial comparing the efficacy of desirudin (Revasc) with that of unfractionated heparin in patients having a total hip replacement.
    Eriksson BI; Ekman S; Lindbratt S; Baur M; Bach D; Torholm C; Kälebo P; Close P
    J Bone Joint Surg Am; 1997 Mar; 79(3):326-33. PubMed ID: 9070519
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Direct thrombin inhibition with Rec-hirudin CGP 39393 as prophylaxis of thromboembolic complications after total hip replacement.
    Eriksson BI; Kälebo P; Ekman S; Lindbratt S; Kerry R; Close P
    Thromb Haemost; 1994 Aug; 72(2):227-31. PubMed ID: 7831657
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A comparison of recombinant hirudin with a low-molecular-weight heparin to prevent thromboembolic complications after total hip replacement.
    Eriksson BI; Wille-Jørgensen P; Kälebo P; Mouret P; Rosencher N; Bösch P; Baur M; Ekman S; Bach D; Lindbratt S; Close P
    N Engl J Med; 1997 Nov; 337(19):1329-35. PubMed ID: 9358126
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A fixed-dose combination of low molecular weight heparin with dihydroergotamine versus adjusted-dose unfractionated heparin in the prevention of deep-vein thrombosis after total hip replacement.
    Horbach T; Wolf H; Michaelis HC; Wagner W; Hoffmann A; Schmidt A; Beck H
    Thromb Haemost; 1996 Feb; 75(2):246-50. PubMed ID: 8815569
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Coagulation activation markers in the prediction of venous thrombosis after elective hip surgery.
    Cofrancesco E; Cortellaro M; Corradi A; Ravasi F; Bertocchi F
    Thromb Haemost; 1997 Feb; 77(2):267-9. PubMed ID: 9157579
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Biologic effects of recombinant hirudin (CGP 39393) in human volunteers. European Hirudin in Thrombosis Group.
    Verstraete M; Nurmohamed M; Kienast J; Siebeck M; Silling-Engelhardt G; Büller H; Hoet B; Bichler J; Close P
    J Am Coll Cardiol; 1993 Oct; 22(4):1080-8. PubMed ID: 8409044
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Hirudin CGP 39393 as thromboprophylaxis.
    Williams DJ; Mahomed A
    Lancet; 1996 Jun; 347(9014):1561-2. PubMed ID: 8684139
    [No Abstract]   [Full Text] [Related]  

  • 9. Prevention of deep vein thrombosis after hip replacement: randomised comparison between unfractionated heparin and low molecular weight heparin.
    Leyvraz PF; Bachmann F; Hoek J; Büller HR; Postel M; Samama M; Vandenbroek MD
    BMJ; 1991 Sep; 303(6802):543-8. PubMed ID: 1655136
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Adjusted versus fixed-dose subcutaneous heparin in the prevention of deep-vein thrombosis after total hip replacement.
    Leyvraz PF; Richard J; Bachmann F; Van Melle G; Treyvaud JM; Livio JJ; Candardjis G
    N Engl J Med; 1983 Oct; 309(16):954-8. PubMed ID: 6621623
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Recombinant hirudin in the prevention of venous thromboembolism in patients undergoing elective hip surgery.
    Agnelli G; Sonaglia F
    Semin Thromb Hemost; 1997; 23(2):143-8. PubMed ID: 9200338
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Prevention of thrombosis with subcutaneous recombinant hirudin in heparin-induced thrombocytopenia type II. A pilot study].
    Huhle G; Hoffmann U; Hoffmann I; Harenberg J; Heene DL
    Dtsch Med Wochenschr; 2000 Jun; 125(22):686-91. PubMed ID: 10874895
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Safety and efficacy of recombinant hirudin (CGP 39 393) versus heparin in patients with stable angina undergoing coronary angioplasty.
    van den Bos AA; Deckers JW; Heyndrickx GR; Laarman GJ; Suryapranata H; Zijlstra F; Close P; Rijnierse JJ; Buller HR; Serruys PW
    Circulation; 1993 Nov; 88(5 Pt 1):2058-66. PubMed ID: 8222099
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Desirudin: a review of its use in the management of thrombotic disorders.
    Matheson AJ; Goa KL
    Drugs; 2000 Sep; 60(3):679-700. PubMed ID: 11030473
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Prevention of deep vein thrombosis after elective hip surgery. A randomized trial comparing low molecular weight heparin with standard unfractionated heparin.
    Levine MN; Hirsh J; Gent M; Turpie AG; Leclerc J; Powers PJ; Jay RM; Neemeh J
    Ann Intern Med; 1991 Apr; 114(7):545-51. PubMed ID: 1848054
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Clinical utility of prothrombin fragment 1+2, thrombin antithrombin III complexes and D-dimer measurements in the diagnosis of deep vein thrombosis following total hip replacement.
    Cofrancesco E; Cortellaro M; Corradi A; Ravasi F; Bertocchi F
    Thromb Haemost; 1998 Mar; 79(3):509-10. PubMed ID: 9531030
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Economic evaluation of desirudin vs heparin in deep vein thrombosis prevention after hip replacement surgery.
    Levin LA; Horst M; Bergqvist D
    Pharmacoeconomics; 1998 Jan; 13(1 Pt 2):111-8. PubMed ID: 10176145
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Low-molecular-weight heparin (enoxaparin) as prophylaxis against venous thromboembolism after total hip replacement.
    Bergqvist D; Benoni G; Björgell O; Fredin H; Hedlundh U; Nicolas S; Nilsson P; Nylander G
    N Engl J Med; 1996 Sep; 335(10):696-700. PubMed ID: 8703168
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Prevention of major venous thromboembolism following total hip or knee replacement: a randomized comparison of low-molecular-weight heparin with unfractionated heparin (ECHOS Trial).
    Haas S; Breyer HG; Bacher HP; Fareed J; Misselwitz F; Victor N; Weber J;
    Int Angiol; 2006 Dec; 25(4):335-42. PubMed ID: 17164738
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Markers of hemostatic system activation during thromboprophylaxis with recombinant hirudin in total hip replacement.
    Cofrancesco E; Cortellaro M; Leonardi P; Corradi A; Ravasi F; Bertocchi F
    Thromb Haemost; 1996 Mar; 75(3):407-11. PubMed ID: 8701398
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.